Potential Biomarkers in Atrial Fibrillation: Insight Into Their Clinical Significance

J Cardiovasc Pharmacol. 2021 Aug 1;78(2):184-191. doi: 10.1097/FJC.0000000000001042.

Abstract

In risk-stratifying patients with atrial fibrillation (AF), physicians rely heavily on clinical parameters that provide risk scores and determine treatment strategies. There has been increasing research on potential biomarkers in the blood that could more accurately determine both risk of complications in AF and risk of incidence of AF. This review highlights the clinical significance of 5 novel biomarkers that have been shown to be linked to AF. These biomarkers are carbohydrate antigen 125, galectin-3, growth differentiation factor-15, a member of the interleukin 1 receptor family, IL1RL1 (ST2), and N-terminal pro B-type natriuretic peptide.

Publication types

  • Review

MeSH terms

  • Action Potentials
  • Animals
  • Atrial Fibrillation / blood*
  • Atrial Fibrillation / diagnosis
  • Atrial Fibrillation / physiopathology
  • Atrial Fibrillation / therapy
  • Atrial Function*
  • Biomarkers / blood*
  • Blood Proteins
  • CA-125 Antigen / blood
  • Clinical Decision-Making
  • Galectins / blood
  • Growth Differentiation Factor 15 / blood
  • Heart Atria / metabolism*
  • Heart Atria / physiopathology
  • Heart Rate
  • Humans
  • Membrane Proteins / blood
  • Natriuretic Peptide, Brain / blood
  • Peptide Fragments / blood
  • Predictive Value of Tests
  • Prognosis
  • Receptors, Interleukin-1 Type I / blood

Substances

  • Biomarkers
  • Blood Proteins
  • CA-125 Antigen
  • GDF15 protein, human
  • Galectins
  • Growth Differentiation Factor 15
  • IL1R1 protein, human
  • LGALS3 protein, human
  • MUC16 protein, human
  • Membrane Proteins
  • Peptide Fragments
  • Receptors, Interleukin-1 Type I
  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain